Selecta Biosciences Inc
NASDAQ:SELB
Selecta Biosciences Inc
Revenue
Selecta Biosciences Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Selecta Biosciences Inc
NASDAQ:SELB
|
Revenue
$48.7m
|
CAGR 3-Years
94%
|
CAGR 5-Years
296%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
See Also
What is Selecta Biosciences Inc's Revenue?
Revenue
48.7m
USD
Based on the financial report for Jun 30, 2023, Selecta Biosciences Inc's Revenue amounts to 48.7m USD.
What is Selecta Biosciences Inc's Revenue growth rate?
Revenue CAGR 5Y
296%
Over the last year, the Revenue growth was -62%. The average annual Revenue growth rates for Selecta Biosciences Inc have been 94% over the past three years , 296% over the past five years .